We are proud to present the
Stem Cell Summit 2018, to be held in Boston, MA. The
Stem Cell Summit provides information on cutting-edge developments in all areas of
stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of
stem cells. This summit comprises of presentations, panels and round-table discussions to highlight pre-clinical and clinical studies in regenerative medicine, immunotherapy, stem cell reprogramming, cell therapy in diabetes, regulatory policies regarding stem cell research, manufacturing and other relevant topics.
The 15th Stem Cell Summit includes two conferences including the joint plenary session:
Joint Sessions:
- Plenary Keynote: Historical Perspective and State of the Industry
- Round Table Sessions
- Lunch Session: Regulatory Challenges in Cell Therapy
- Award Ceremony and Closing Keynote Session - Predictions for the Future
Stem Cell Research & Regenerative Medicine:
- Advances in Adult Stem Cell Research
- Advances in Pluripotent Stem Cell Research
- Translation to the Clinic: What's in the Pipeline
- Revolution in Immunotherapy
Stem Cell Product Development & Commercialization:
- Stem Cells for Drug Discovery and Disease Modeling
- Partnering between Industry, Academia and CROs to Advance Research
- Manufacturing and Scalable Processes for Cell Therapy
- Funding & Commercialization of Cell Therapy
We hope to see you in Boston!
PLENARY KEYNOTE SPEAKERS
- Hans Keirstead, Chief Executive Officer, AIVITA Biomedical
- Erin Kimbrel, Senior Director of Development, Astellas Institute for Regenerative Medicine
- Douglas Melton, Professor, Harvard University
- Evan Y. Snyder, Professor and Director, Program in Stem Cell & Regenerative Biology, Sanford-Burnham Medical Research Institute
PLENARY SPEAKERS
- Melody Eble, Director, Global Regulatory Affairs, Janssen Research & Development, LLC
- Toshio Miyata, Executive Director, Health & Global Policy Institute
Stem Cell Product Development & Commercialization - DISTINGUISHED SPEAKERS
- Gregory Bonfiglio, Managing Partner, Proteus Venture Partners
- Wilfried Dalemans, Chief Technical Officer, Tigenix
- Matthew Durdy, Chief Business Officer, Cell Therapy Catapult
- James Hickman, Chief Scientist, Hesperos
- Patrick Keenan, Managing Director, Prevail Partners
- Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM)
- Kevin Murray, Vice President, Global Sales, BioSpherix Medical
- Gail Naughton, Chief Executive Officer, Histogen
- Brock Reeve, Executive Director, Harvard Stem Cell Institute
- Gil Sambrano, Vice President of Portfolio Development and Review, California Institute for Regenerative Medicine
- Katy Spink, Managing Partner, Dark Horse Consulting
- Emily Titus, Director, Technology Development, Centre for Commercialization of Regenerative Medicine (CCRM)
- Alain Vertès, Managing Director, NxR Biotechnologies GmbH
Stem Cell Research & Regenerative Medicine - DISTINGUISHED SPEAKERS
- Deborah Ascheim, Chief Medical Officer, Capricor
- Kristin Baldwin, Professor, Investigator, Dorris Neuroscience Center, Department of Neuroscience California Campus, Scripps Institute
- Buddhadeb Dawn, Director, Midwest Stem Cell Therapy Center
- MyLinh Duong, Senior Scientist, Bellicum Pharmaceuticalsss
- Kevin Eggan, Professor in the Department of Stem Cell and Regenerative Biology, Harvard University
- Jacques Galipeau, Don and Marilyn Anderson Professor in Oncology; Assistant Dean for Therapeutics Discovery and Development; Director, Program for Advanced Cell Therapy, University of Wisconsin in Madison
- Silviu Itescu, Chief Executive Officer & Managing Director, Mesoblast
- Hardy T S Kagimoto, President and Chief Executive Officer, Healios K.K (RIKEN Venture)
- Douglas Losordo, Chief Medical Officer, Senior Vice President of Clinical, Medical & Regulatory Affairs, Caladrius Biosciences
- Richard Morgan, Vice President, Immunotherapy, Bluebird Bio
- Mahendra Rao, Vice President for Regenerative Medicine, New York Stem Cell Foundation
- Scott Olson, Assistant Professor, Program in Regenerative Medicine, University of Texas
- Paul Rennert, President & CSO, Aleta Biotherapeutics
- Khalid Shah, Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging, Harvard Medical School
- Sally Temple, Scientific Director, Neural Stem Cell Institute
- Anthony Ting, Vice President, Athersys
- Bob Valamehr, Vice President, Cancer Immunotherapy & Reprogramming Biology, Fate Therapeutics Inc.
Please fill in your name and email to receive the 2017 conference agenda of this event.
The 2017 agenda is available as PDF under downloads at the right side of the page,
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Venue
Hyatt Regency Boston1 Ave De Lafayette
Boston, MA 02111
1-617-912-1234
Discounted Group Rate: $269.00/night
Discount Deadline is March 16, 2018
Toll Free Reservations Phone Number
1-888-421-1442
Mention GTCbio Event for the discounted group rate.
Book your room online using this link:
https://aws.passkey.com/go/gbio
